Search research articles
Contact Us
Filters
Showing results (61-70 of 78) with videos related to
Page
of 8
Sort By:
Cancer Research
|
August 17, 2001
A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line
P Perego, M De Cesare, P De Isabella, et al.
Cancer Research
|
October 5, 2001
Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin
M De Cesare, G Pratesi, P Perego, et al.
British Journal of Cancer
|
May 9, 2007
A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group
S Pignata, G Scambia, C Pisano, et al.
European Review for Medical and Pharmacological Sciences
|
July 30, 2013
Intravesical chemo-immunotherapy in non muscle invasive bladder cancer
D Leopardo, S C Cecere, M Di Napoli, et al.
Journal of Medicinal Chemistry
|
September 21, 2001
Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity
S Dallavalle, A Ferrari, B Biasotti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 19, 2015
Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial
D Lorusso, G Scambia, S Pignata, et al.
Gynecologic Oncology
|
November 4, 2019
Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial
D Lorusso, G Ferrandina, N Colombo, et al.
Cancer Immunology, Immunotherapy : CII
|
April 17, 2025
Association of peripheral monocytic myeloid-derived suppressor cells with molecular subtypes in single-center endometrial cancer patients receiving carboplatin + paclitaxel/avelumab (MITO-END3 trial)
C D'Alterio, G Rea, M Napolitano, et al.
British Journal of Cancer
|
September 15, 2011
Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer
C K Lee, R J Simes, C Brown, et al.
ESMO Open
|
December 6, 2025
Homologous recombination repair status in advanced endometrial cancer: an exploratory biomarker analysis from the randomized, phase II MITOEND 3 trial
M Bartoletti, A Passarelli, A Fagotti, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 78) with videos related to
Sort By:
Page
of 8
Cancer Research
|
August 17, 2001
A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line
P Perego, M De Cesare, P De Isabella, et al.
Cancer Research
|
October 5, 2001
Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin
M De Cesare, G Pratesi, P Perego, et al.
British Journal of Cancer
|
May 9, 2007
A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group
S Pignata, G Scambia, C Pisano, et al.
European Review for Medical and Pharmacological Sciences
|
July 30, 2013
Intravesical chemo-immunotherapy in non muscle invasive bladder cancer
D Leopardo, S C Cecere, M Di Napoli, et al.
Journal of Medicinal Chemistry
|
September 21, 2001
Novel 7-oxyiminomethyl derivatives of camptothecin with potent in vitro and in vivo antitumor activity
S Dallavalle, A Ferrari, B Biasotti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 19, 2015
Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial
D Lorusso, G Scambia, S Pignata, et al.
Gynecologic Oncology
|
November 4, 2019
Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial
D Lorusso, G Ferrandina, N Colombo, et al.
Cancer Immunology, Immunotherapy : CII
|
April 17, 2025
Association of peripheral monocytic myeloid-derived suppressor cells with molecular subtypes in single-center endometrial cancer patients receiving carboplatin + paclitaxel/avelumab (MITO-END3 trial)
C D'Alterio, G Rea, M Napolitano, et al.
British Journal of Cancer
|
September 15, 2011
Prognostic nomogram to predict progression-free survival in patients with platinum-sensitive recurrent ovarian cancer
C K Lee, R J Simes, C Brown, et al.
ESMO Open
|
December 6, 2025
Homologous recombination repair status in advanced endometrial cancer: an exploratory biomarker analysis from the randomized, phase II MITOEND 3 trial
M Bartoletti, A Passarelli, A Fagotti, et al.
Page
of 8